Allison DeAngelis

1 week ago | statnews.com | Allison DeAngelis

A private equity firm has stepped in to finance a biological research lab at Harvard University, administrators said Monday, while also launching a biotech alongside it that will develop new therapies for metabolic conditions. As Harvard grapples with severe financing cuts undertaken by the Trump administration, some university officials believe the unusual arrangement could be at least one model to fund other academic research in the future.

1 week ago | share.google | Allison DeAngelis

A private equity firm has stepped in to finance a biological research lab at Harvard University, administrators said Monday, while also launching a biotech alongside it that will develop new therapies for metabolic conditions. As Harvard grapples with severe financing cuts undertaken by the Trump administration, some university officials believe the unusual arrangement could be at least one model to fund other academic research in the future.

1 week ago | bostonglobe.com | Allison DeAngelis

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. A private equity firm has stepped in to finance a biological research lab at Harvard University, administrators said Monday, while also launching a biotech alongside it that will develop new therapies for metabolic conditions.

2 weeks ago | statnews.com | Matthew Herper |Jason Mast |Allison DeAngelis

National Resilience, a startup that has raised over $2 billion by promising to transform drug manufacturing, said Monday that it would “wind down” many of its facilities. But what remains of the firm will seek to raise an additional $250 million from existing investors and continue to build its business and seek more capital. Through a bit of financial engineering, an affiliate of the company that holds leases for six of the company’s manufacturing facilities is filing for bankruptcy.

3 weeks ago | statnews.com | Adam Feuerstein |Elaine Chen |Allison DeAngelis

On this week’s episode of “The Readout LOUD”: The Food and Drug Administration’s AI adventure, a deep look inside Novo Nordisk’s obesity stumble, and finally, another big M&A deal in biotech. The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it’s always a fun podcast when we can discuss a biotech acquisition.